Skip to content

MULTICENTER, RANDOMIZED, PARALLEL-GROUP, DOUBLE-BLIND CLINICAL TRIAL OF SUPERIORITY IN EFFICACY AND SAFETY OF THE FIXED-DOSE COMBINATION OF CEPHALEXIN AND AMBROXOL (BIOBRONCOL®) VERSUS CEPHALEXIN IN THE TREATMENT OF ACUTE BACTERIAL PHARYNGOTONSILLITIS IN ADULTS

MULTICENTER, RANDOMIZED, PARALLEL-GROUP, DOUBLE-BLIND CLINICAL TRIAL OF SUPERIORITY IN EFFICACY AND SAFETY OF THE FIXED-DOSE COMBINATION OF CEPHALEXIN AND AMBROXOL (BIOBRONCOL®) VERSUS CEPHALEXIN IN THE TREATMENT OF ACUTE BACTERIAL PHARYNGOTONSILLITIS IN ADULTS

Status
Unknown
Phases
Phase 3
Study type
Interventional
Source
REPEC
Registry ID
PER-103-20
Enrollment
290
Registered
2021-02-03
Start date
2021-01-01
Completion date
Unknown
Last updated
2026-03-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

J039 Acute tonsillitis, unspecified Acute tonsillitis, unspecified

Interventions

None listed

Sponsors

Instituto Quimioterapico S.A.
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: -Patients between 18 - 80 years old -Clinical diagnosis of bacterial pharyngotonsillitis (4 or more criteria of Modified Centor by McIsaac) with rapid antigenic detection test for positive GABHS, or less than 4 criteria of Modified Centor by McIsaac with rapid antigenic detection test for positive GABHS. -Signed informed consent form. -Rapid SARS COV-2 Test Negative

Exclusion criteria

Exclusion criteria: -Concomitant respiratory infections such as acute otitis media, acute sinusitis, pneumonia, subpharyngeal infections or tonsillar abscesses. -History of rheumatic heart disease or valve dysfunction of unknown etiology -Immunosuppression -Skin rash -Medical history of kidney disease or liver failure. -Patients with some type of cancer. -History of recurrent or recent pharyngotonsillitis (more than 3 episodes in the last 6 months or 1 episode in the last month) -Have received oral antibiotics in the last 7 days prior to enrollment in the study or have received cephalosporins in the last three months. -History of hypersensitivity to amoxicillin or type 1 hypersensitivity to penicillin. -History of hypersensitivity to ambroxol. -Pregnancy or lactation. -Concurrent treatment with another antibiotic or with corticosteroids.

Design outcomes

Primary

MeasureTime frame
Scale for assessing the intensity of symptoms of group A-beta hemolytic streptococcus tonsillopharyngitis NAME OF THE RESULT: Resolution of the severity of symptoms PERIOD OF TIME WHERE TE MEASUREMENT WILL BE CONDUCTED AND WHICH WILL ALLOW OBTAINING THE PRIMARY RESULT: Day 3,10, 15;Rapid antigenic detection test for GABHS NAME OF THE RESULT: Microbiological cure PERIOD OF TIME WHERE TE MEASUREMENT WILL BE CONDUCTED AND WHICH WILL ALLOW OBTAINING THE PRIMARY RESULT: Day 15

Secondary

MeasureTime frame
Scale for assessing the intensity of symptoms of group A-beta hemolytic streptococcus tonsillopharyngitis NAME OF THE RESULT: Resolution of the severity of symptoms PERIOD OF TIME WHERE TE MEASUREMENT WILL BE CONDUCTED AND WHICH WILL ALLOW OBTAINING THE PRIMARY RESULT: Day 3,10, 15;Rapid antigenic detection test for GABHS NAME OF THE RESULT: Microbiological cure PERIOD OF TIME WHERE TE MEASUREMENT WILL BE CONDUCTED AND WHICH WILL ALLOW OBTAINING THE PRIMARY RESULT: Day 15;Scale for assessing the intensity of symptoms of group A-beta hemolytic streptococcus tonsillopharyngitis NAME OF THE RESULT: early resolution of symptoms PERIOD OF TIME WHERE TE MEASUREMENT WILL BE CONDUCTED AND WHICH WILL ALLOW OBTAINING THE PRIMARY RESULT: Day 3;Report in CRF NAME OF THE RESULT: Report of serious adverse events PERIOD OF TIME WHERE TE MEASUREMENT WILL BE CONDUCTED AND WHICH WILL ALLOW OBTAINING THE PRIMARY RESULT: During the 15 days

Countries

Peru

Outcome results

None listed

Source: REPEC (via WHO ICTRP) · Data processed: Apr 4, 2026